Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.900
+0.070 (3.83%)
At close: Mar 11, 2026, 4:00 PM EDT
1.840
-0.060 (-3.16%)
After-hours: Mar 11, 2026, 7:48 PM EDT
Invivyd Revenue
In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth. Invivyd had revenue of $17.21M in the quarter ending December 31, 2025, with 24.51% growth.
Revenue (ttm)
$53.43M
Revenue Growth
+110.47%
P/S Ratio
10.05
Revenue / Employee
$534,260
Employees
100
Market Cap
536.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.43M | 28.04M | 110.47% |
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 170.44M |
| Century Therapeutics | 113.34M |
| Fulcrum Therapeutics | 80.00M |
| ADC Therapeutics | 75.21M |
| Prothena Corporation | 9.68M |
| Ocugen | 4.41M |
| Lyell Immunopharma | 41.00K |
IVVD News
- 6 days ago - Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - GlobeNewsWire
- 6 days ago - Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire
- 9 days ago - Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - GlobeNewsWire
- 9 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies - GlobeNewsWire
- 5 weeks ago - Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - GlobeNewsWire
- 7 weeks ago - Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - GlobeNewsWire